Citigroup
TVTX icon

Citigroup’s Travere Therapeutics TVTX Stock Holding History

Citigroup’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100
Closed -$3K – 7396
2020
Q4 		$3K Hold
100
– – ﹤0.01% 7213
2020
Q3 		$2K Hold
100
– – ﹤0.01% 7322
2020
Q2 		$2K Hold
100
– – ﹤0.01% 7427
2020
Q1 		$1K Sell
100
-2,400
-96% -$36.1K ﹤0.01% 7521
2019
Q4 		$36K Hold
2,500
– – ﹤0.01% 6590
2019
Q3 		$29K Buy
+2,500
New +$41.3K ﹤0.01% 6510
2019
Q2 		– Sell
-1,200
Closed -$27K – 7861
2019
Q1 		$27K Sell
1,200
-5,600
-82% -$124K ﹤0.01% 6796
2018
Q4 		$154K Buy
6,800
+6,700
+6,700% +$167K ﹤0.01% 5273
2018
Q3 		$3K Buy
+100
New +$2.86K ﹤0.01% 7576
2018
Q2 		– Sell
-2,000
Closed -$45K – 7743
2018
Q1 		$45K Sell
2,000
-200
-9% -$4.76K ﹤0.01% 6243
2017
Q4 		$46K Sell
2,200
-100
-4% -$2.29K ﹤0.01% 6242
2017
Q3 		$57K Hold
2,300
– – ﹤0.01% 5928
2017
Q2 		$45K Sell
2,300
-1,300
-36% -$23.6K ﹤0.01% 5862
2017
Q1 		$66K Sell
3,600
-800
-18% -$15.6K ﹤0.01% 5513
2016
Q4 		$83K Buy
4,400
+4,200
+2,100% +$85.9K ﹤0.01% 5883
2016
Q3 		$4K Buy
+200
New +$3.81K ﹤0.01% 6829

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citigroup's TVTX Position: Q1 2026 in Review

Citigroup increased its Travere Therapeutics (TVTX) stake by 0.07% in Q1 2026, buying an estimated $598 and bringing the position to 27,131 shares worth $806K. The position accounts for ﹤0.01% of the portfolio, ranked #3248.

Citigroup first reported a position in TVTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $8.14M in Q1 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Citigroup held 27,131 shares of Travere Therapeutics worth $806K as of Q1 2026.
  • Citigroup bought 20 Travere Therapeutics shares in Q1 2026, an estimated $598.
  • Travere Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3248 holding.
  • Citigroup first reported a position in Travere Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Citigroup's Travere Therapeutics position peaked at $8.14M in Q1 2023.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.